Patient investors are still waiting for news on the dialysis specialist's expected merger.
News & Analysis: NxStage Medical
Shares tumble after management dials back guidance. Here's what investors need to know.
Here's the good news the dialysis specialist needed.
Find out why concerns about the dialysis specialist's merger are getting worse.
NXTM earnings call for the period ending March 31, 2018.
An increasing discount to the buyout price for the dialysis specialist's stock is raising concerns.
Find out how the dialysis specialist's business fared in the shadow of a buyout bid.
The pending acquisition by Fresenius put NxStage's second-quarter financial report in a much different context.
These stocks helped push markets higher. Find out why.
News that the company has accepted a buyout offer sends shares higher.